Factory 99% Lorlatinib Powder CAS 1454846-35-5 Chemical Intermediate Lorlatinib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A774
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Lorlatinib
• CAS: 1454846-35-5
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Lorlatinib
Appearance	White Powder
CAS NO.	1454846-35-5
Storage	Keep in a cool, dry, dark location

 

Lorlatinib is an orally administered tablet primarily composed of Lorlatinib, which serves as a potent and selective inhibitor for anaplastic lymphoma kinase (ALK) and ROS1. It is also known by its brand names Lorbrena and Lorviqua.

 

1. ALK-Positive NSCLC: Lorlatinib is primarily indicated for the treatment of patients with ALK-positive, locally advanced, or metastatic non-small cell lung cancer (NSCLC).
2. ROS1-Positive NSCLC: As a third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI), Lorlatinib is also effective in treating NSCLC with ROS1 mutations.
3. NTRK Gene Fusion Tumors: Lorlatinib can be used to treat patients with tumors that have an NTRK gene fusion, regardless of the tumor type or genetic variation.

1. Inhibition of Tumor Growth: By inhibiting the abnormal signal caused by ALK or ROS1 mutations, Lorlatinib effectively blocks the growth and spread of tumors.
2. Broad Coverage of Resistance Mutations: Compared to other ALK TKIs, Lorlatinib has broader coverage of known ALK resistance mutations, making it a highly effective treatment option.
3. Central Nervous System Penetration: Lorlatinib demonstrates good penetration into the central nervous system, addressing brain metastases that may occur in NSCLC patients.